RA Capital Management 13F holdings, Q2 2019
Holdings as of June 30, 2019 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 25 US equity positions worth $1.9bn in its Q2 2019 13F filing. The largest position was ASND at 25.5% of the reported book, followed by WVE and ZOGENIX INC. Against the Q1 2019 filing, it opened 4 new positions, added to 4 and reduced 3 among the top 25 holdings.
What did RA Capital Management own in Q2 2019? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2019 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 25.5% | $475.9m | 4,132,442 | 0% | held |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 10.9% | $202.9m | 7,775,207 | 0% | held |
| 3 | ZOGENIX INC | 9.5% | $177.9m | 3,722,504 | 56% | added | |
| 4 | RA PHARMACEUTICALS INC | 7.4% | $137.0m | 4,858,260 | 0% | held | |
| 5 | SYNTHORX INC | 7.1% | $131.4m | 9,724,598 | 0% | held | |
| 6 | EIDOS THERAPEUTICS INC | 6.1% | $112.7m | 2,162,671 | 0% | held | |
| 7 | ORCHARD THERAPEUTICS PLC | 3.8% | $71.5m | 5,108,330 | 0% | held | |
| 8 | TGTX TG THERAPEUTICS INC | Healthcare | 3.2% | $59.5m | 6,880,323 | -16% | reduced |
| 9 | MYOVANT SCIENCES LTD | 3.2% | $59.2m | 6,545,642 | 85% | added | |
| 10 | CRINETICS PHARMACEUTICALS INC | 2.5% | $46.9m | 1,875,209 | 0% | held | |
| 11 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.2% | $41.5m | 1,884,782 | 0% | held |
| 12 | DICERNA PHARMACEUTICALS INC | 2.1% | $38.7m | 2,456,669 | 0% | held | |
| 13 | ARVN ARVINAS INC | Healthcare | 2.0% | $37.1m | 1,688,412 | -21% | reduced |
| 14 | PREVAIL THERAPEUTICS INC | 1.9% | $36.2m | 2,743,625 | – | new | |
| 15 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.9% | $34.5m | 1,340,828 | -59% | reduced |
| 16 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.8% | $32.7m | 1,119,963 | – | new |
| 17 | KALA PHARMACEUTICALS INC | 1.6% | $28.9m | 4,537,478 | 0% | held | |
| 18 | SHOCKWAVE MED INC | 1.5% | $28.3m | 495,608 | 0% | held | |
| 19 | DTIL PRECISION BIOSCIENCES INC | 1.3% | $24.4m | 1,842,366 | 0% | held | |
| 20 | SLDB SOLID BIOSCIENCES INC | 1.1% | $21.3m | 2,689,444 | 0% | held | |
| 21 | ALEC ALECTOR INC | Healthcare | 1.0% | $19.0m | 1,000,000 | 0% | held |
| 22 | G1 THERAPEUTICS INC | 0.8% | $14.8m | 483,990 | 33% | added | |
| 23 | XFOR X4 PHARMACEUTICALS INC | 0.7% | $12.9m | 861,393 | – | new | |
| 24 | SCPHARMACEUTICALS INC | 0.6% | $10.4m | 3,247,005 | 14% | added | |
| 25 | ODONATE THERAPEUTICS INC | 0.4% | $7.3m | 200,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.